TWI443090B - 作為代謝性麩胺酸受體2(mglu2 受體)之正向調節劑之雜環化合物 - Google Patents
作為代謝性麩胺酸受體2(mglu2 受體)之正向調節劑之雜環化合物 Download PDFInfo
- Publication number
- TWI443090B TWI443090B TW097119263A TW97119263A TWI443090B TW I443090 B TWI443090 B TW I443090B TW 097119263 A TW097119263 A TW 097119263A TW 97119263 A TW97119263 A TW 97119263A TW I443090 B TWI443090 B TW I443090B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- phenyl
- pyrazol
- ylmethyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93186907P | 2007-05-25 | 2007-05-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200902501A TW200902501A (en) | 2009-01-16 |
TWI443090B true TWI443090B (zh) | 2014-07-01 |
Family
ID=39714050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW097119263A TWI443090B (zh) | 2007-05-25 | 2008-05-23 | 作為代謝性麩胺酸受體2(mglu2 受體)之正向調節劑之雜環化合物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9242933B2 (fr) |
EP (1) | EP2167464B1 (fr) |
JP (1) | JP5615700B2 (fr) |
KR (1) | KR20100017372A (fr) |
CN (1) | CN101687790B (fr) |
AU (1) | AU2008257559B2 (fr) |
BR (1) | BRPI0812163A2 (fr) |
CA (1) | CA2686651C (fr) |
ES (1) | ES2530431T3 (fr) |
IL (1) | IL201995A0 (fr) |
MX (1) | MX2009012749A (fr) |
NZ (1) | NZ581127A (fr) |
RU (1) | RU2479577C2 (fr) |
TW (1) | TWI443090B (fr) |
WO (1) | WO2008145616A1 (fr) |
ZA (1) | ZA200908017B (fr) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
PT2203439E (pt) | 2007-09-14 | 2011-02-11 | Ortho Mcneil Janssen Pharm | 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas |
JP5433579B2 (ja) | 2007-09-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1,3−二置換−4−フェニル−1h−ピリジン−2−オン |
PE20091523A1 (es) | 2007-12-20 | 2009-10-29 | Novartis Ag | Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k) |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
RU2510396C2 (ru) | 2008-09-02 | 2014-03-27 | Янссен Фармасьютикалз, Инк. | 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
WO2010043396A1 (fr) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Dérivés d’indole et de benzomorpholine en tant que modulateurs des récepteurs métabotropiques du glutamate |
AU2009319387B2 (en) | 2008-11-28 | 2012-05-10 | Addex Pharma S.A. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
JP2012525326A (ja) * | 2009-05-01 | 2012-10-22 | ラクオリア創薬株式会社 | Trpm8拮抗剤としてのスルファモイル安息香酸誘導体 |
NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
WO2010130422A1 (fr) | 2009-05-12 | 2010-11-18 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Dérivés de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2 |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
BR112012009574A2 (pt) * | 2009-10-22 | 2019-09-24 | Univ Vanderbilt | potencializador alostérico de mglura, composições, e métodos de tratamento de disfunção neurológica |
WO2011116356A2 (fr) * | 2010-03-19 | 2011-09-22 | Sanford-Burnham Medical Research Institute | Modulateurs allostériques positifs de mglurs de type 2 |
US8664214B2 (en) | 2010-03-30 | 2014-03-04 | AbbVie Deutschland GmbH & Co. KG | Small molecule potentiators of metabotropic glutamate receptors I |
US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
EP2643320B1 (fr) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | Dérivés de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2 |
EP2699569B1 (fr) * | 2011-04-22 | 2017-08-30 | Jasco Pharmaceuticals, LLC | Inhibiteurs d'aminopyrimidine kinase |
US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8642774B2 (en) | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
US8796467B2 (en) | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
US8716277B2 (en) | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
SI2841428T1 (sl) | 2012-04-24 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
ME03336B (fr) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibiteurs d'adn-pk |
MY191087A (en) | 2013-03-15 | 2022-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
EP3424920B1 (fr) | 2013-10-17 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Co-cristaux de (s)-n-méthyl-8-(1-((2 '-méthyl-[4,5'-bipyrimidin] -6-yl)amino) propan-2-yl)quinoline-4-carboxamide et leurs dérivés deutérés en tant qu'inhibiteurs de l'adn-pk |
EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
EP3431106B1 (fr) | 2014-01-21 | 2020-12-30 | Janssen Pharmaceutica NV | Combinaisons comprenant des modulateurs allostériques positifs de récepteurs glutamatergiques métabotropes de sous-type 2 et leur utilisation |
KR20200126026A (ko) | 2014-01-21 | 2020-11-05 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
WO2015116856A2 (fr) * | 2014-01-29 | 2015-08-06 | City Of Hope | Antagonistes du récepteur x de farnésoïde |
US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
USRE49517E1 (en) | 2014-08-15 | 2023-05-02 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
PT3180329T (pt) | 2014-08-15 | 2020-06-08 | Janssen Pharmaceuticals Inc | Triazóis como inibidores do recetor nr2b |
PL3319963T3 (pl) | 2015-07-09 | 2020-06-01 | Janssen Pharmaceutica Nv | Podstawione 4-azaindole i ich zastosowanie jako modulatorów receptora GluN2B |
PL3344248T3 (pl) * | 2015-09-02 | 2022-07-18 | Trevena, Inc. | Zawierające sześcioczłonowy aza-heterocykl związki modulujące receptor opioidowy delta oraz sposoby ich wykorzystywania i wytwarzania |
CA3014314A1 (fr) | 2016-02-10 | 2017-08-17 | Janssen Pharmaceutica Nv | 1,2,3-triazoles substitues utilises comme modulateurs de nmda selectifs de nr2b |
AU2017335648B2 (en) | 2016-09-27 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
WO2018152293A1 (fr) | 2017-02-17 | 2018-08-23 | Trevena, Inc. | Composés modulateurs du récepteur delta des opioïdes contenant des aza-hétérocycles à 5 chaînons, leurs procédés d'utilisation et de fabrication |
US11225487B2 (en) | 2017-02-17 | 2022-01-18 | Trevena, Inc. | 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same |
CN116730920A (zh) | 2017-02-17 | 2023-09-12 | 文涵治疗有限公司 | Ag-10的制备方法、其中间体及其盐 |
WO2018168898A1 (fr) * | 2017-03-15 | 2018-09-20 | 大日本住友製薬株式会社 | Nouveau composé de benzimidazolone et son utilisation pharmaceutique |
JP2021517142A (ja) | 2018-03-15 | 2021-07-15 | アクザム ソシエタ ペル アチオニ | 置換ピラゾールffa4/gpr120受容体作動薬 |
JP2021518381A (ja) | 2018-03-23 | 2021-08-02 | エイドス セラピューティクス,インコーポレイティド | Ag10を使用するttrアミロイドーシスの治療方法 |
EP3774732A4 (fr) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
JP7469293B2 (ja) | 2018-08-17 | 2024-04-16 | エイドス セラピューティクス,インコーポレイティド | Ag10の製剤 |
US20210380558A1 (en) * | 2018-10-18 | 2021-12-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Beta-catenin and b-cell lymphoma 9 (bcl9) inhibitors |
AU2020292994A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
EP3983073A1 (fr) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyrazolo[4,3-b]pyridines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
WO2020249796A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Carbamates de pyrazine et leur utilisation en tant que modulateurs du récepteur glun2b |
WO2020249799A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Carbamates de pyridine et leur utilisation en tant que modulateurs du récepteur glun2b |
TW202112774A (zh) | 2019-06-14 | 2021-04-01 | 比利時商健生藥品公司 | 經取代之吡唑并-吡啶醯胺及其作為glun2b受體調節劑之用途 |
CN110878052B (zh) * | 2019-12-11 | 2021-05-07 | 山东大学 | 一种含有fxr激动剂的化合物及其制备方法和应用 |
EP4085056A1 (fr) | 2020-01-03 | 2022-11-09 | Berg LLC | Amides polycycliques utilisés en tant que modulateurs d'ube2k pour le traitement du cancer |
CN115960047A (zh) * | 2023-01-10 | 2023-04-14 | 中国药科大学 | 一种3-苯基-1h-吡唑类化合物及其用途 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3880544D1 (de) * | 1987-04-21 | 1993-06-03 | Basf Ag | P-phenoxy-phenoxymethyl-fuenfring-heteroaromaten. |
FR2656610B1 (fr) | 1989-12-29 | 1992-05-07 | Sanofi Sa | Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique. |
JPH07138258A (ja) * | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
US20020143007A1 (en) | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
FR2766822B1 (fr) | 1997-07-30 | 2001-02-23 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP3694774B2 (ja) * | 1997-10-31 | 2005-09-14 | 大鵬薬品工業株式会社 | フェニルカルボン酸誘導体 |
JP2007119478A (ja) * | 1998-07-15 | 2007-05-17 | Teijin Ltd | チオベンズイミダゾール誘導体 |
AR026414A1 (es) | 1999-11-10 | 2003-02-12 | Takeda Pharmaceutical | Compuetos heterociclicos de 5 miembros que contienen nitrogeno |
CN1198819C (zh) | 2000-01-17 | 2005-04-27 | 帝人株式会社 | 苯并咪唑衍生物 |
AU2001234420A1 (en) * | 2000-02-03 | 2001-08-14 | Eli Lilly And Company | Potentiators of glutamate receptors |
JP2001226450A (ja) * | 2000-02-16 | 2001-08-21 | Sumitomo Bakelite Co Ltd | 光半導体封止用エポキシ樹脂組成物及び光半導体装置 |
CO5221057A1 (es) * | 2000-03-02 | 2002-11-28 | Aventis Cropscience Sa | Componentes y composiciones plagicidas |
ES2353077T3 (es) * | 2000-08-10 | 2011-02-25 | Mitsubishi Tanabe Pharma Corporation | Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos. |
KR100884709B1 (ko) * | 2000-09-14 | 2009-02-19 | 미쓰비시 타나베 파마 코퍼레이션 | 신규한 아미드 유도체의 광학 활성체 및 그의 의약적 용도 |
JP4656787B2 (ja) * | 2001-09-28 | 2011-03-23 | 大鵬薬品工業株式会社 | Cdc25脱リン酸化酵素阻害活性を有する新規カルボン酸誘導体及び医薬 |
JP4430941B2 (ja) * | 2002-01-18 | 2010-03-10 | メルク エンド カムパニー インコーポレーテッド | Edg受容体作動薬 |
US20040063744A1 (en) | 2002-05-28 | 2004-04-01 | Tao Wang | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
JP2004123732A (ja) * | 2002-09-10 | 2004-04-22 | Takeda Chem Ind Ltd | 5員複素環化合物 |
AU2004222626B2 (en) | 2003-03-21 | 2010-06-24 | H. Lundbeck A/S | Substituted p-diaminobenzene derivatives |
UA81668C2 (en) * | 2003-05-01 | 2008-01-25 | Бристол-Майерс Сквибб Компани | Normal;heading 1;heading 2;ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS |
MY141255A (en) * | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
HUP0304101A3 (en) * | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
JP2007223901A (ja) * | 2004-03-24 | 2007-09-06 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
JP4621939B2 (ja) * | 2004-03-31 | 2011-02-02 | イハラケミカル工業株式会社 | 5−ヒドロキシ−4−チオメチルピラゾール化合物の製造方法 |
JP2007246396A (ja) | 2004-04-28 | 2007-09-27 | Ihara Chem Ind Co Ltd | 5−ジフルオロメトキシ−4−チオメチルピラゾール化合物の製造方法 |
EA014419B1 (ru) | 2004-05-24 | 2010-12-30 | Эмджен Инк. | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения |
AU2005267883A1 (en) | 2004-07-30 | 2006-02-09 | Merck & Co., Inc. | Indanone potentiators of metabotropic glutamate receptors |
CA2574956A1 (fr) * | 2004-07-30 | 2006-02-09 | Merck & Co., Inc. | Potentialisateurs d'acetophenone heterocycliques de recepteurs metabotropiques du glutamate |
TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
JP2006117568A (ja) | 2004-10-20 | 2006-05-11 | Mitsubishi Pharma Corp | チオフェン環を有する新規アミド誘導体及びその医薬としての用途 |
CN101048157A (zh) * | 2004-10-25 | 2007-10-03 | 默克公司 | 代谢型谷氨酸受体的杂环二氢茚酮增强剂 |
US7700365B2 (en) | 2004-10-29 | 2010-04-20 | Mayo Foundation For Medical Education And Research | Vitamin D deficiencies |
ATE461188T1 (de) | 2004-11-22 | 2010-04-15 | Lilly Co Eli | Verstärker von glutamat-rezeptoren |
CA2596993A1 (fr) * | 2005-02-07 | 2006-08-10 | Mitsubishi Pharma Corporation | Derive de tetrahydronaphtalene optiquement actif |
CA2598531A1 (fr) | 2005-02-24 | 2006-08-31 | Merck & Co., Inc. | Potentialisateurs de benzazole de recepteurs de glutamate metabotropique |
MX2008000141A (es) | 2005-06-27 | 2008-04-07 | Exelixis Inc | Moduladores de lxr basados en imidazol. |
EP1912939A1 (fr) | 2005-08-12 | 2008-04-23 | AstraZeneca AB | Isoindolones potentiateurs du récepteur glutamate métabotropique |
EA015632B9 (ru) | 2006-05-24 | 2012-08-30 | Эли Лилли Энд Компани | Агонисты fxr |
AU2007324696B2 (en) | 2006-11-24 | 2012-10-04 | Ac Immune S.A. | N- (methyl) -1H- pyrazol- 3 -amine, N- (methyl) -pyridin-2-amine and N- (methyl) -thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. Alzheimer's |
KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Lxr 및 fxr 조절자 |
-
2008
- 2008-05-23 TW TW097119263A patent/TWI443090B/zh not_active IP Right Cessation
- 2008-05-23 CA CA2686651A patent/CA2686651C/fr not_active Expired - Fee Related
- 2008-05-23 JP JP2010508867A patent/JP5615700B2/ja not_active Expired - Fee Related
- 2008-05-23 CN CN200880017425.6A patent/CN101687790B/zh not_active Expired - Fee Related
- 2008-05-23 BR BRPI0812163-0A2A patent/BRPI0812163A2/pt not_active IP Right Cessation
- 2008-05-23 NZ NZ581127A patent/NZ581127A/en not_active IP Right Cessation
- 2008-05-23 EP EP08759978.3A patent/EP2167464B1/fr not_active Not-in-force
- 2008-05-23 KR KR1020097024595A patent/KR20100017372A/ko not_active Application Discontinuation
- 2008-05-23 AU AU2008257559A patent/AU2008257559B2/en not_active Ceased
- 2008-05-23 MX MX2009012749A patent/MX2009012749A/es active IP Right Grant
- 2008-05-23 RU RU2009148336/04A patent/RU2479577C2/ru not_active IP Right Cessation
- 2008-05-23 ES ES08759978T patent/ES2530431T3/es active Active
- 2008-05-23 US US12/126,174 patent/US9242933B2/en not_active Expired - Fee Related
- 2008-05-23 WO PCT/EP2008/056378 patent/WO2008145616A1/fr active Application Filing
-
2009
- 2009-11-08 IL IL201995A patent/IL201995A0/en unknown
- 2009-11-13 ZA ZA2009/08017A patent/ZA200908017B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200902501A (en) | 2009-01-16 |
EP2167464B1 (fr) | 2014-12-03 |
CA2686651C (fr) | 2015-11-24 |
CN101687790B (zh) | 2015-02-11 |
WO2008145616A1 (fr) | 2008-12-04 |
JP2010527974A (ja) | 2010-08-19 |
RU2479577C2 (ru) | 2013-04-20 |
BRPI0812163A2 (pt) | 2014-12-16 |
ES2530431T3 (es) | 2015-03-02 |
KR20100017372A (ko) | 2010-02-16 |
ZA200908017B (en) | 2015-08-26 |
EP2167464A1 (fr) | 2010-03-31 |
US9242933B2 (en) | 2016-01-26 |
US20080300260A1 (en) | 2008-12-04 |
IL201995A0 (en) | 2010-06-16 |
AU2008257559A1 (en) | 2008-12-04 |
NZ581127A (en) | 2012-06-29 |
JP5615700B2 (ja) | 2014-10-29 |
MX2009012749A (es) | 2010-03-10 |
CA2686651A1 (fr) | 2008-12-04 |
AU2008257559B2 (en) | 2013-10-10 |
CN101687790A (zh) | 2010-03-31 |
RU2009148336A (ru) | 2011-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI443090B (zh) | 作為代謝性麩胺酸受體2(mglu2 受體)之正向調節劑之雜環化合物 | |
JP4879165B2 (ja) | メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体 | |
US20050234046A1 (en) | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | |
JP2007532563A5 (fr) | ||
AU2015360583B2 (en) | Small molecule inhibitors of fibrosis | |
US10919885B2 (en) | Compounds and uses thereof | |
CN114728170B (zh) | 对核受体具有活性的化合物 | |
US20190152960A1 (en) | Apoptosis Inhibitors | |
US20220298168A1 (en) | Compounds and uses thereof | |
US20230078764A1 (en) | Compounds and uses thereof | |
JP2009533400A (ja) | アミノメチルピリジン誘導体、この調製方法、およびこの治療的使用 | |
US20230069174A1 (en) | Nitrogen-containing heterocyclic autotaxin inhibitor, and composition containing same and use thereof | |
US20090099199A1 (en) | Organic compounds | |
BRPI0710177A2 (pt) | arilsulfonas heterocìclicas adequadas para tratar distúrbios que respondem à modulação do receptor 5ht6 de serotonina | |
US7317025B2 (en) | Non-peptidic NPY Y2 receptor inhibitors | |
CA3005516C (fr) | Composes de 1,3,4-thiadiazole et leur utilisation pour traiter le cancer | |
US7786155B2 (en) | Organic compounds | |
TW201317217A (zh) | 吡唑類化合物 | |
EP3148992A1 (fr) | Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques | |
JP5449320B2 (ja) | 3−インダゾリル−4−ピリジルイソチアゾール類 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |